Comparing a new drug to stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares a new investigational drug (AZD0120) with a standard stem cell transplant for people with newly diagnosed multiple myeloma who have already completed initial treatment. The goal is to see if the new drug works as well as or better than the transplant in keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of multiple myeloma that is measurable (by blood or urine tests).
- You must have completed 4 to 6 cycles of standard initial treatment (such as a combination of drugs) and your disease must be stable or better.
- You must be well enough to undergo high-dose chemotherapy followed by a stem cell transplant (performance status 0 or 1).
- You must have adequate organ and bone marrow function.
- You must not have certain other conditions like plasma cell leukemia, amyloidosis, or prior treatment with certain cell therapies (CAR-T) or BCMA-targeted drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
Hear when a new Newly Diagnosed Multiple Myeloma (NDMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.